Physician profile
Joshua Carson
NPI 1326298936
$51,727.86
in general payments reported to CMS, 2019-2025
7 companies · $740 in 2025
The $740 reported for 2025 was more than what a typical Surgical Critical Care provider received nationally (typical 2025 total: $234).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $8,422 · 2020: $15K · 2021: $126 · 2022: $8,589 · 2023: $12K · 2024: $7,221 · 2025: $740.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $15K · Honoraria: $3,000 · Food and Beverage: $834 · Travel and Lodging: $363.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $15,264.00 |
| Honoraria | $3,000.00 |
| Food and Beverage | $833.96 |
| Travel and Lodging | $362.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avita Medical Americas, LLC | $20,874.74 | 2019-2025 | Recell, Permeaderm, Cohealyx |
| Mallinckrodt Hospital Products INC. | $16,990.01 | 2020-2024 | Stratagraft |
| Mallinckrodt Enterprises LLC | $6,547.39 | 2019 | |
| Trevena, INC. | $6,052.31 | 2022-2023 | Olinvyk |
| Integra Lifesciences Corporation | $867.13 | 2019-2021 | |
| Polynovo North America LLC | $271.28 | 2023-2024 | Novosorb Btm |
| Vericel Corporation | $125.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joshua Carson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.